ImmunoTargets and Therapy (Nov 2020)
All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective
Abstract
André Jefremow,1,2 Markus F Neurath1,2 1Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; 2Deutsches Zentrum Immuntherapie (DZI), Erlangen, GermanyCorrespondence: André JefremowDepartment of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GermanyEmail [email protected]: Chronic inflammatory diseases like inflammatory bowel diseases (IBD) or psoriasis represents a worldwide health burden. Researchers provided great achievements in understanding the origin of these diseases leading to improved therapeutic options. The discovery of cytokines like tumor necrosis factor-α or transforming growth factor-β are examples for these efforts. Interleukin 12 (IL 12) and interleukin 23 (IL 23) represent different important cytokines in this regard. They both belong to the interleukin 12 family and are related by sharing the subunit p40. Ustekinumab is an antibody that blocks p40 and thereby interleukins 12 and 23. Trials showed promising results in treating IBD patients with this drug. Consequently, new questions arose about the distinct features of IL 12 and 23. This review focuses on these interleukins regarding their functions in the healthy and inflamed gut and provides an overview about the results from in vitro and in vivo studies as well as clinical trials.Keywords: inflammatory bowel diseases, Crohn’s disease, ulcerative colitis, interleukin 12, interleukin 23
